Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 8Terminated 4Recruiting 3Unknown 2Active not recruiting 2Withdrawn 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 24Lymphoma 11Lymphoma, Non-Hodgkin 9Prostatic Neoplasms 8Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 7Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Hodgkin Disease 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Lymphoma, Large-Cell, Immunoblastic 2Immunoblastic Lymphadenopathy 2Subcutaneous panniculitis-like T-cell lymphoma 1Spinal Cord Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Plasmablastic Lymphoma 1Pituitary Neoplasms 1Neoplasms, Experimental 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Neoadjuvant Therapy 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 5Vincristine 4Doxorubicin 3fludarabine phosphate 2Psychiatric Rehabilitation 2Prednisone 2Prednisolone 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Flow Cytometry 2Etoposide 2Cytarabine 2Cyclosporine 2Busulfan 2Antilymphocyte Serum 2Alemtuzumab 2sargramostim 1ruxolitinib 1motesanib diphosphate 1carbendazim 1Transplantation 1Therapeutics 1Steroids 1Sensitivity and Specificity 1S-1,2-dichlorovinyl-N-acetylcysteine 1Ritonavir 1Radiotherapy 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Prednisone × Clear all
NCT03613428 2018-08-03

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Sichuan University

Phase 1/2 Unknown
12 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00363090 2013-09-20

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
84 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡